[Design and birth of drugs].
Today the design of new clinical entities uses highly sophisticated techniques. This design is a step by step procedure: first selection and validation of the therapeutic targets, where the contribution of genomics is very important; then, setting up the different screening tests. This step permits to detect the potentially active molecules, which will be optimised, before being tested in healthy volunteers and then in patients.
Maffrand
Jean-Pierre
JP
Lehner
Jean-Pierre
JP
Le Fur
Gérard
G
D002986:Clinical Trials as Topic; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D023281:Genomics; D006801:Humans